moxifloxacin has been researched along with penicillanic acid in 10 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (penicillanic acid) | Trials (penicillanic acid) | Recent Studies (post-2010) (penicillanic acid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,764 | 327 | 880 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Almassi, GH; Brown, KR; Edmiston, CE; Kehl, KS; Krepel, CJ; Lewis, BD; Loehrl, TA; Seabrook, GR; Smith, TL; Somberg, LB; Towne, JB | 1 |
| Giordano, P; Herrington, J; Kowalsky, S; Pertel, P; Song, J | 1 |
| Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Hampel, B; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, N | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Johnson, PD; Trevillyan, JM | 1 |
| Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q | 1 |
| Aral, M; Ates, S; Doganer, A; Nazik, S; Orak, F; Yalcinkaya, KT | 1 |
1 review(s) available for moxifloxacin and penicillanic acid
| Article | Year |
|---|---|
Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2017 |
5 trial(s) available for moxifloxacin and penicillanic acid
| Article | Year |
|---|---|
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Tolerance; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Skin Diseases, Bacterial | 2005 |
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Topics: Abdominal Abscess; Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendicitis; Aza Compounds; Bacterial Infections; Cross Infection; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Intestinal Perforation; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Stomach Rupture; Treatment Outcome | 2006 |
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines; Skin; Skin Diseases, Bacterial | 2011 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
4 other study(ies) available for moxifloxacin and penicillanic acid
| Article | Year |
|---|---|
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Imipenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines | 2005 |
Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Buruli Ulcer; Debridement; Fluoroquinolones; Glucocorticoids; Humans; Male; Moxifloxacin; Mycobacterium ulcerans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prednisolone; Quinolines; Rifampin; Young Adult | 2013 |
The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Superinfection | 2023 |